<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20191027045252N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-01-10</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the efficacy of in vivo shock therapy with corticosteroid injection in the treatment of piriformis syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the efectiveness of Radial Extracorporeal Shock wave Therapy and corticosteroid injection of piriformis muscle for treatment patients suffering of piriformis syndrome</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>35</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/43295</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Simple randomization, in which each member of society has an equal and independent chance of being elected. The randomization procedure will use a randomized block with quadratic and binary blocks. Given the sample size of 35 people, 8 quadruple blocks and 1 binary blocks will be generated and numbered using the permutations method. Using the random number table, blocks will be placed together to form a sequence of patients assigned to treatment groups. Therefore, prior to selecting the participants, the type of treatment they receive will be unaware, and the random sequence generated during the study will be unpredictable, Blinding description: Due to the difference in the nature of the therapeutic intervention in the two groups, only the data analyzer will be blind.</study_design>
      <phase>3</phase>
      <hc_freetext>Piriformis syndrome.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Patients undergoing shockwave therapy, three sessions, each lasting 7 to 10 days. Shockwave is performed with the Storz Medical Shock Wave MP100. Each session of shockwave therapy with 2000 pulses and a total of 6000 pulses in three sessions, energy flux density equal to 0.18 mJ / mm², 5 Hz frequency, 4 bar pressure rate, Dose per treatment equal to 0.18 mJ / mm2 = 2,000 360 mJ / mm2 and Total energy dose (TED) equal to 1.080 J / mm2. Intervention 2: Control group: Patients treated with 40 mg methylprednisolone plus 1 cc lidocaine 1% undergo sonography in the piriformis muscle.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The extent of pain relief can be shared according to the Visual Analogue Scale.

When:
Access started from 1400

To whom:
Study data will be available only to researchers working in academic and scientific institutions.

Conditions:
Access to the data will be allowed for epidemiological study and can be sent by email.

Where to obtain:
To receive data, you could call 00989123190373 or contact arastoo.yousefi@gmail.com.

How to obtain:
Individuals who request data, must provide their academic, Scientific documents and the reason for their requests to arastoo.yousefi@gmail.com.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Arash Babaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 4, Banafshe Deadend, Second Deadend, Hoseini Ave, North Shahrdari, West Sarv Blvd, Saadat Abad, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 2235 9437</telephone>
        <email>arastoo.yousefi@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Arash Babaei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No 4, Banafshe Deadend, Second Deadend, Hoseini Ave, North Shahrdari, West Sarv Blvd, Saadat Abad, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1998774714</zip>
        <telephone>+98 21 2235 9437</telephone>
        <email>arastoo.yousefi@gmail.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Chronic pain in Batuk, thigh and lower extremity for at least 3 months
Patients must be over 20 years of age
Screening of all patients for lumbar disc herniation and lumbar radiculopathy by MRI.
Their pain intensity should be at least 5 out of 10 according to the Visual Analogue Scale criteria</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Symptoms of lumbar discus, coxopathy, mechanical or inflammatory disorders of the sacroiliac joint
Any inflammatory, infectious, or pelvic abnormalities
Have a pregnancy or pregnancy plan
Have a history of disc surgery and any epidural block over the past 6 months.
Patients who do not go for follow-up for any reason.
Changes in the patient's treatment according to the physician's opinion or other treatment by the patient during the study</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G57.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Lesion of sciatic nerve</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Patients undergoing shockwave therapy, three sessions, each lasting 7 to 10 days. Shockwave is performed with the Storz Medical Shock Wave MP100. Each session of shockwave therapy with 2000 pulses and a total of 6000 pulses in three sessions, energy flux density equal to 0.18 mJ / mm², 5 Hz frequency, 4 bar pressure rate, Dose per treatment equal to 0.18 mJ / mm2 = 2,000 360 mJ / mm2 and Total energy dose (TED) equal to 1.080 J / mm2.</i_keyword>
      <i_keyword>Control group: Patients treated with 40 mg methylprednisolone plus 1 cc lidocaine 1% undergo sonography in the piriformis muscle.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Severity of pain. Timepoint: Baseline, 7, 30, 60, and 90 days after Intervention. Method of measurement: Visual Analogue Scale.</prim_outcome>
      <prim_outcome>Quality of Life. Timepoint: Baseline and 30 days after Intervention. Method of measurement: 36-Item Short Form Survey (SF-36) questionnaire.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-09-23</approval_date>
        <contact_name>Ethics Committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Next to Milad Tower, Hemmat Highway, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
